MedinCell S.A. (ENXTPA: MEDCL)
Health Care · Pharmaceuticals · FR
€24.14
-2.97% today · +38.9% 1Y
MedinCell S.A. (ENXTPA: MEDCL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.04B and employs 141 people.
Over the last twelve months the share price has gained 38.9%, trading between 16.55 and 39.68.
Tweenvest scores MedinCell S.A. across four factors: quality 32/100, value 56/100, growth 0/100. Its strongest factor is value.
MEDCL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.04B
- Revenue (TTM)
- $27.99M
- P/E
- —
- EPS
- -0.94
- Dividend yield
- —
- Beta (5Y)
- 0.98
- 52-week high
- €39.68
- 52-week low
- €16.55
- Avg volume (3M)
- —
- Shares outstanding
- 35.91M
- Employees
- 141
- Next earnings
- —
About MedinCell S.A.
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
- ISIN
- FR0004065605
- Founded
- 2003
- Listed since
- Oct 8, 2018
- Exchange
- Euronext Paris
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,237.51 | -1.43% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.29 | +0.76% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.48 | -1.36% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.89 | -0.64% |
Figures last refreshed Aug 18, 2026.